had been well until 1 month before admission, when she noted fatigue, a 25-pound weight loss with concurrent otitis media, and sinus infections lasting 4 weeks. She was evaluated by her primary care physician and found to have new-onset anemia and
Search Results
Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia
Sandipkumar H. Patel, Sumithira Vasu, Ling Guo, Olivia Lemaster, John C. Byrd, and Alison Walker
Outcomes From a Patient-Centered, Interprofessional, Palliative Consult Team in Oncology
Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah
study can be found on the Alberta Health Services website. 11 Edmonton Symptom Assessment System: The ESAS 12 is a self-report questionnaire that asks patients to rate the severity of their current suffering regarding 9 common symptoms (pain, fatigue
Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
Kamya Sankar and Brady L. Stein
provided molecular targets for drug development in both PV and ET. The primary goals of treatment for MPNs are to reduce the risk of thrombosis and alleviate systemic symptom burden (eg, fatigue, pruritus, microvascular symptoms, symptomatic splenomegaly
Personalizing Medicine Through Personalized Communication: Individuality of the Patient Across Borders and Cultures
Giuseppe Curigliano
in all geo-cultural groups are particularly traumatized by the overt physical changes from breast cancer treatments. The stigmata of breast surgery and of treatment-related side effects such as hair loss and fatigue confirm to women the reality of
Are We on the Same Page? Patient and Provider Perceptions About Exercise in Cancer Care: A Focus Group Study
Agnes Smaradottir, Angela L. Smith, Andrew J. Borgert, and Kurt R. Oettel
mentioned fatigue most often as a significant barrier to exercise (50%). Other barriers included symptoms of disease, such as dyspnea, pain, and impaired mobility. Side effects of treatment, including nausea, vomiting, diarrhea, neuropathic pain, emotional
Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial
Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell
survival. 1 Proposed mechanisms for this positive effect on chemotherapy treatment tolerance include exercise-related amelioration of specific symptoms or toxicities that cause treatment reductions or delays, including neutropenia, fatigue, and neuropathy
Discussing Colorectal Cancer
Paul F. Engstrom
Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia
Susana M. Campos, Mei Sheng Duh, Patrick Lefebvre, and James Rosberg
. Factors influencing quality of life in cancer patents: anemia and fatigue . Semin Oncol 1998 ; 25 : 43 – 46 . 4 Curt GA . Impact of fatigue on quality of life in oncology patients . Semin Hematol 2000 ; 37 : 14 – 17 . 5 Sobrero
Letter to the Editor: Chicken Noodle Soup (Capsule) for the Soul?
Lindsey A. Kluck and Ronald S. Go
Re: Sriram Yennurajalingam, Nizar M. Tannir, Janet L. Williams, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients with Advanced Cancer. J Natl Compr Canc Netw 2017
CLO20-061: A Meta-Analysis on the Safety of Panobinostat Compared to Eltozumab and Ixazomib for the Treatment of Multiple Myeloma
Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat, and Qian Zhang
.11) Figure 1 . Paobinostat had a significantly lower risk of lymphopenia (OR 0.25 95% CI 0.15-0.42, p=<0.0001) Panobinostat was however, associated with two times more risk of anemia (OR 2.82 95% CI 1.82-4.38, p=<0.0001), fatigue (OR 2.36 95% CI 1.64-3.38, p
